Development of selective degradation strategies towards mutant transcription factors
- Institution
- Icahn School of Medicine at Mount Sinai, NY
- Principal investigator
- James J Bieker
- Funding
- $211K
- Duration
- 2024–2026
Moonbase score
Still being scored
Abstract
SUMMARY Transcription factors play essential roles in establishing the correct gene expression patterns unique to each cell type. These finely controlled patterns can fall apart if a mutation resides within a critical factor. In the hematopoietic system, this can lead to anemia, dysplasia, or leukemia of varying morbidities. Overcoming transcription factor deficits is highly challenging, especially if the mutation is solely in one of the two alleles and if complete removal of the protein’s expression is not an option. Experiments in this proposal addresses the problem in the context of the congenital dyserythropoietic anemia (CDA) caused by a single missense mutation in one allele of the KLF1(EKLF) transcription factor. Technological development of state-of-the-art approaches to selectively target and degrade the mutant variant will be designed and tested. Specifically, the method relies on the cellular introduction of degradative modules (degrons) coupled to targeting motifs based on KLF1/DNA interactions, the details of which are to be based on published and proposed methods of identifying parameters of binding selectivity. These studies, summarized in two Aims that cover (1) in vitro tests and (2) in vivo (cell culture) approaches, will have a transformative effect well beyond the immediate case, as they provide an innovative and distinctive blueprint for the direct removal of problematic proteins in other hematologic and renal diseases caused by monoallelic missense mutations in transcription factor DNA binding domains.
LOADING MOONBASE SCORE
Questions for Icahn School of Medicine at Mount Sinai
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · Icahn School of Medicine at Mount Sinai58
Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ Vaccination
Joshua D Brody · $352K · 2024–2026
- NIH · Icahn School of Medicine at Mount Sinai58
Defining and targeting the lung cancer progenitor cell niche using a high-resolution, multi-omics approach
Daniel Charytonowicz · $55K · 2021–2026
- NIH · Icahn School of Medicine at Mount Sinai48
The Use of Rhythmic Light Therapy to Entrain Gamma Oscillations and the Circadian System in Patients with Alzheimer's Disease and Related Dementias (ADRD)
Mariana Gross Figueiro · $782K · 2021–2027